Evidence map›Paper›PMID 39362210›Full record

ArticleUrologia internationalis2025

Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer.

Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologia internationalis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Immanuel A OppolzerDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Marco J SchnabelDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Selma HammerDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Hannah ZillesDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Maximilian HaasDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Christopher GoßlerDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Maximilian R MüllerDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Maximilian BurgerDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Michael GierthDepartment of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).

methodsA monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.

resultsNine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).

conclusionRegarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.

introductionThe aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).

methodsA monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.

resultsNine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).

conclusionRegarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.

Indexed as

COVID-19Delayed DiagnosisProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm StagingPandemicsRetrospective StudiesSARS-CoV-2Time FactorsClinical dataCOVID-19Delay in diagnosisProstate cancerSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID39362210
PMCPMC11965868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.